There was a lineup of important European drug decisions released today. At the top of the list:
European regulators have given a green light to Glaxosmithkline's OTC version of the obesity drug Xenical.
- check out the report from The Scotsman
ALSO: France's Ipsen announced that the CHMP recommended marketing authorization for Increlex. A formal approval will trigger a $20 million milestone payment to Tercica. Release
> European regulators are recommending the use of Sanofi-Aventis' Plavix for stent patients. Report
> Roche's anemia drug Mircera got a thumb's up from European regulators as well. The therapy has been delayed in the U.S. as the FDA ponders the fate of anemia drugs in the face of new safety data. Report